AZ, Merck link to develop and commercialise cancer drugs

27th July 2017 Uncategorised 0

In a bumper news day for AstraZeneca, the firm announced a deal with Merck & Co to co-develop and co-commercialise Lynparza and selumetinib for multiple cancer types, second-quarter results in line with expectations, initial trial data showing the failure of Imfinzi to boost PFS in lung cancer patients, and other trial data in lung cancer showing the success of Tagrisso in improving PFS.

More: AZ, Merck link to develop and commercialise cancer drugs
Source: News